

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3568787

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST RECORDED AT REEL 34378, FRAME 0972
CONVEYING PARTY DATA	
Name	Execution Date
WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT	10/05/2015
RECEIVING PARTY DATA	
Name:	NEKTAR THERAPEUTICS
Street Address:	455 MISSION BAY BOULEVARD SOUTH
Internal Address:	SUITE 100
City:	SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94070
PROPERTY NUMBERS Total: 7	
Property Type	Number
Application Number:	14323993
Application Number:	14451201
Application Number:	14477606
Application Number:	14517679
Application Number:	14528444
Application Number:	14547633
Application Number:	62080775
CORRESPONDENCE DATA	
Fax Number:	(214)981-3400
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	214-981-3483
Email:	dclark@sidley.com
Correspondent Name:	DUSAN CLARK, ESQ.
Address Line 1:	SIDLEY AUSTIN LLP
Address Line 2:	2001 ROSS AVENUE, SUITE 3600
Address Line 4:	DALLAS, TEXAS 75201
ATTORNEY DOCKET NUMBER:	60595-10020
NAME OF SUBMITTER:	DUSAN CLARK

SIGNATURE:	/Dusan Clark/
DATE SIGNED:	10/14/2015
Total Attachments: 3 source=December 2014 Patent Release#page1.tif source=December 2014 Patent Release#page2.tif source=December 2014 Patent Release#page3.tif	

RELEASE OF SECURITY INTEREST IN PATENTS

WHEREAS, pursuant to that certain Grant of Security Interest in United States Patents, executed as of November 26, 2014 (the "Patent Security Agreement"), recorded in the United States Patent and Trademark Office at Reel 34378, Frame 0972 on December 4, 2014, NEKTAR THERAPEUTICS, a Delaware corporation ("Releasee"), granted to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Collateral Agent ("Releasor"), to secure the Indenture Obligations, a continuing interest in the following (collectively, the "Patent Collateral"): (i) all of the Releasee's rights, title and interest in, to and under the United States patents and patent applications (the "Patents") set forth on Schedule A attached hereto, in each case together with (ii) all proceeds (as such term is defined in the Uniform Commercial Code of the State of New York as in effect from time to time) and products of the Patents, and (iii) all causes of action arising prior to or after the date thereof for infringement of any of the Patents or unfair competition regarding the same; and

WHEREAS, Releasee has requested and Releasor has agreed to provide a document suitable for recording in the United States Patent and Trademark Office evidencing and effecting the release, relinquishment and discharge of its security interest in the Patent Collateral.

NOW, THEREFORE, in consideration of and in exchange for good and valuable consideration, Releasor hereby agrees as follows:

1. Defined Terms. All capitalized terms used but not otherwise defined herein have the meanings given to them in the Patent Security Agreement.
2. Release of Security Interest. Releasor hereby, without any representation and warranty and without any recourse to Releasor, releases, relinquishes and discharges its security interest in the Patent Collateral.

IN WITNESS WHEREOF, Releasor has caused this Release of Security Interest
in Patents to be duly executed as of October 5, 2015.

WELLS FARGO BANK, NATIONAL
ASSOCIATION,
As Collateral Agent

By: Raymond Deili Coili
Name: Raymond Deili Coili
Title: Vice President

*Release of December 2014 Wells Fargo
Security Interest in Patents*

PATENT
REEL: 036855 FRAME: 0561

SCHEDULE A

Patent Collateral

Title	Serial No.	Filing Date
MULTI-ARM POLYMER PRODRUGS	14/323,993	07/03/2014
PARTICULATE MATERIALS	14/451,201	08/04/2014
OLIGOMER-NITROIMIDAZOLE ANTI- INFECTIVE CONJUGATES	14/477,606	09/04/2014
UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE	14/517,679	10/17/2014
OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS	14/528,444	10/30/2014
OLIGOMER-PROTEIN TYROSINE KINASE INHIBITORS CONJUGATES	14/547,633	11/19/2014
COMBINATION-BASED TREATMENT METHOD	62/080,775	11/17/2014